Skip to main content

Preop Lab Values May ID Risk of Postarthroplasty Joint Infection in Morbid Obesity

Medically reviewed by Carmen Pope, BPharm. Last updated on July 25, 2024.

By Lori Solomon HealthDay Reporter

THURSDAY, July 25, 2024 -- Certain preoperative laboratory values may predict risk of periprosthetic joint infection (PJI) among individuals with morbid obesity undergoing arthroplasty, according to a study published in the July 17 issue of the Journal of Bone & Joint Surgery.

Sagar Telang, from the University of Southern California in Los Angeles, and colleagues sought to identify preoperative laboratory values that may serve as predictors of PJI in patients with morbid obesity undergoing total hip arthroplasty or total knee arthroplasty (TKA). Analysis included 6,780 patients (TKA: 76.7 percent) of whom 47 (0.69 percent) developed PJI within 90 days after surgery.

The researchers found that the rate of PJI was 1.69 percent for patients with a hemoglobin level of <12 g/dL (for females) or <13 g/dL (for males), 2.14 percent for those with a platelet count of <142,000/µL or >417,000/µL, 1.11 percent for those with a neutrophil-lymphocyte ratio (NLR) of >3.31, 1.69 percent for those with a platelet-lymphocyte ratio (PLR) of >182.3, and 1.05 percent for those with a systemic immune-inflammation index (SII) of >776.2. In adjusted analysis, there were significant associations between PJI and an abnormal preoperative NLR (adjusted odds ratio [aOR], 2.38), PLR (aOR, 4.86), SII (aOR, 2.44), platelet count (aOR, 3.50), and hemoglobin level (aOR, 2.62).

"These findings may help surgeons risk-stratify this high-risk patient population," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted July 2024

Read this next

No Weight Loss Benefit Seen for Neoadjuvant Semaglutide Before Weight Loss Surgery

WEDNESDAY, March 12, 2025 -- Neoadjuvant semaglutide before metabolic and bariatric surgery (MBS) is not beneficial in terms of weight loss, according to a research letter...

AAOS: Stopping GLP-1 RAs 14 Days Before Surgery Can Minimize Complications

TUESDAY, March 11, 2025 -- Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications...

Intraoperative Remifentanil, Sufentanil Tied to Poor Postoperative Pain Experience

THURSDAY, March 6, 2025 -- For patients undergoing elective surgery, intraoperative use of remifentanil and sufentanil is independently associated with a poorer postoperative pain...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.